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in the postoperative period and bringing the profession of 
specialist surgeon into disrepute is provocative and laughable. 
I’m surprised that this hearing favoured the ‘expertise’ 
presented by a retired surgical academic, who by his own 
admission had done very little laparoscopic surgery, over 
that of a professor and a specialist intensivist currently at the 
top of their careers.  Surely experienced medical personnel 
should be appointed to hear public grievances?  Those of us 
who are members of the Medical Protection Society (MPS) are 
concerned that in a case like this the legal representatives failed 
dismally. This case should have won hands down. 
   There is a perception among the lay public and litigation 
lawyers that as most of us have some form of medical prot- 
ection there’s no harm in ‘having a go’!  MPS reports suggest 
that medicolegal claims in South Africa have escalated way 
above rates in the rest of the world. It is my impression that 
we in clinical medicine are seen as an easily milked cash cow.  
We are under continual pressure from medical aids, hospital 
groups and the media – and now our very own HPCSA.
   I sincerely hope that the colleague in question has the 
stamina to exercise his rights and appeal against the findings of 
the HPCSA, and that his surgical association reacts strongly to 
this disgraceful decision.
Barry Penn
31 Mountain Road 
Claremont
7708
Well done, SAMA’s Industrial Relations 
Unit!
To the Editor: It is reassuring to know that the South African 
Medical Association, through its Industrial Relations Unit, 
has the capacity to assist doctors, especially hospital doctors, 
should any have reason to believe that they have been 
subjected to unfair labour practices. 
   My own experience is that about 3 years after retirement 
I was phoned by the hospital concerned and told that I had 
received a salary increase some 2 or 3 years before retirement 
for which I had not been paid. I was told that if I supplied my 
bank details I would be paid. Having heard nothing for a year 
I made further enquiries, only to be told that the provincial 
health department concern had no money.
   I had no recourse other than through the SAMA Industrial 
Labour Unit, which was entirely successful in obtaining my 
back pay.
  I don’t hesitate to recommend to all doctors that they should 
become SAMA members, for this and many other reasons!
T L Williams 
PO Box 86
Lidgetton 
3270
Selective serotonin reuptake inhibitors 
in children and adolescents
To the Editor: The introduction of the selective serotonin 
reuptake inhibitors (SSRIs) was widely viewed as an important 
advance in clinical psychopharmacology, not only because 
of their broad-spectrum efficacy but also because of their 
tolerability and safety advantages, particularly compared with 
the older tricyclic antidepressants (TCAs) and monoamine 
oxide inhibitors (MAOIs). Subsequently there has been 
considerable controversy about this class of agents, partly 
because of concerns about the extent to which they have been 
injudiciously prescribed for ‘cosmetic’ problems rather than 
for genuine psychopathology,1 and partly because of concerns 
regarding their adverse effects. Most recently, attention has 
been paid to the appropriate use of SSRIs in children and 
adolescents.
   The ‘Drug Alert’ published by the National Adverse Drug 
Event Monitoring Centre in the September 2005 SAMJ2 is 
singularly unhelpful in this regard. The report takes a far more 
conservative stance than that taken by regulators in the USA, 
the UK and the EU; it may be misleading by implication and 
omission; and (if followed to the letter) it may cause child and 
adolescent psychiatric patients significant harm.
   The ‘Drug Alert’ warns practitioners on four points. First, 
‘None of the SSRIs are currently approved in South Africa 
for any indication in children and adolescents.’ It should 
be pointed out, however, that fluoxetine is registered with 
the US Food and Drug Administration (FDA) for child and 
adolescent depression and several of the SSRIs (fluvoxamine, 
sertraline, and fluoxetine) are also FDA-registered for child and 
adolescent obsessive-compulsive disorder (OCD).3 Practitioners 
should also be aware that decisions about whether to submit 
pharmaceutical agents to the Medicines Control Council for 
registration of particular indications may often be made on the 
basis of cost rather than scientific or clinical considerations.  
   Second, ‘SSRIs have been associated with an increase in the 
risk of suicidal thinking and behaviour (suicidality) in children 
and adolescents with MDD [major depressive disorder] and 
other psychiatric disorders.’ However, as the drug alert also 
states, ‘no suicides occurred’ in the 24 trials involving over 
4 400 patients. In addition, a systematic review4 published 
recently found no significant difference in the risk of suicide 
in patients taking SSRIs compared with those taking TCAs. 
As several commentators have pointed out, patients with 
overt suicidal ideation are excluded from clinical trials and 
the heterogeneous nature of the trial designs employed (use of 
different definitions and assessments of self-harm in different 
study populations) further contributes to the difficulty of 
interpreting the data. The trials quoted were not designed 
to address the question of whether SSRIs increase suicidal 
ideation, and cannot in fact do so.5
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   Third, products ‘containing citalopram, escitalopram, 
fluvoxamine, paroxetine, sertraline and venlafaxine are 
contraindicated in children under 18 years of age’. While 
many regulatory authorities have cautioned practitioners 
about possible adverse events of these agents, so far none 
have taken so inflexible an approach as to say that they are all 
‘contraindicated’ in children and adolescents.  The European 
Medicines Agency in the same press release referred to by 
the MCC concedes that: ‘It is recognised that a doctor may 
sometimes take a decision based on the individual clinical 
needs of a child or an adolescent to use these products for the 
treatment of depression or anxiety. The CHMP [Committee for 
Medicinal Products for Human Use] is recommending that in 
these cases patients be monitored carefully for the appearance 
of suicidal behaviour, self-harm or hostility, particularly at the 
beginning of treatment.’6
   It must be remembered that TCAs are not effective in child 
and adolescent depression, while SSRIs have been shown to 
be effective (on their own and in combination with cognitive 
behavioural therapy) for child and adolescent depression, and 
as a sole intervention in some childhood anxiety disorders, 
especially OCD.7-10 Fluoxetine, the only SSRI not on the MCC’s 
‘contraindicated’ list, is not always tolerated by younger 
patients, especially those who have severe anxiety, and is also 
not available in any form except 20 mg capsules in most of the 
state sector, making appropriate dosing difficult. The effect 
of implementing the MCC recommendations as published 
would be to deprive child and adolescent patients with these 
disorders of available, effective and potentially life-saving 
alternative medications.  
   Depression is a common, disabling, and potentially fatal 
disorder that is substantially and unequivocally associated with 
suicide and deliberate self-harm in children and adolescents. 
A large recent Swedish forensic study11 showed that only 13% 
and 4% respectively of children and adolescents who actually 
committed suicide had received any antidepressant medication 
at all; youth suicide is far more likely to occur due to untreated 
depression than the adverse effects of any antidepressant. It 
should also be noted that since the advent of the SSRIs in 1988, 
suicide rates have decreased significantly in many countries.12,13
   Fourth, ‘Discontinuation of SSRIs, especially abrupt 
discontinuation, commonly leads to significant withdrawal 
symptoms.’ While it is true that discontinuation symptoms 
can be seen with some SSRIs after abrupt discontinuation, 
this warning runs the risk of conflating SSRIs, which are not 
associated with dependence, with medication classes such as 
the benzodiazepines, where dependence is an acknowledged 
risk.
   In view of the above points we urge practitioners to note 
that these warnings from the MCC do not seem to reflect a 
balanced view of current scientific thinking, and may have 
significant adverse consequences for patients if implemented 
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inflexibly. We would argue that the SSRIs do have an important 
role to play in psychiatric practice, including that of child and 
adolescent psychiatry, and that clinicians should, as always, 
balance the benefits and risks for any particular patient and 
keep the interests of the patient paramount. Obtaining an 
expert opinion from a child and adolescent psychiatrist would 
be useful in situations where a practitioner is unsure.  We hope 
that the MCC will urgently reconsider the wording of this 
directive, in the interests of the many young patients who may 
otherwise be deprived of necessary and effective treatments.  
S M Hawkridge
S Seedat
R Emsley
P Carey
D J Stein   
Cross-University Brain-Behaviour Initiative
Departments of Psychiatry and Mental Health
University of Cape Town and 
Slellenbosch University 
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Rocephin – the thin end of the wedge 
To the Editor: I am sure I speak for many colleagues who have 
been cajoled, squeezed, begged and pressurised by medical 
aids, hospital administrators, pharmacists and representatives 
to stick to formularies to the point at which, backs against the 
wall, we say, ‘No more!’  The ‘thin edge of the wedge’ for me is 
the Rocephin issue.  
   I have grown up with Rocephin.  For me, rightly or wrongly, 
Rocephin is the drug that diminishes my anxiety, oh so slightly, 
over the safety of my patients; that may prevent meningitis 
secondary to sinus surgery; and that may stop a child’s 
otorrhoea when other drugs have failed and prevent him or her 
from developing mastoiditis.
   But despite evidence that many generics are inferior,1 the 
pressure is on me not to use Rocephin, but to prescribe a 
generic, for the vast saving of about R5 per dose.
   When will this pressure stop?  If I surrender on the Rocephin 
issue, what comes next? Are the medical aid administrators, 
the hospital managers and the pharmaceutical buyers willing 
to share the medical risk that I face on a daily basis?  Will 
they stand in the dock with me one day, and admit to using 
medications that are not proven to be equal in efficacy?
   We hear so much about ‘sharing risk’ nowadays. The best 
way those pressurising me to use ‘their’ not ‘my’ choice of 
drugs can share risk, is by sharing my risk.  What about, as 
a suggestion, paying all or part of my medical indemnity 
insurance?
   I’m not looking for handouts.  I’m not looking for perverse 
incentives.  I don’t even know, or care, whether the ‘local’ 
generic ceftriaxone is equivalent to Rocephin.  For a saving 
of only R5 a dose? I learn from one generic manufacturer that 
their local factory manufacturing quality is excellent, and then I 
hear that the drug I am interested in is allegedly manufactured 
in Turkey, shipped to Germany, and then to South Africa where 
it is distributed.
   For me there is a line I dare not cross, on the other side of 
which my autonomy stands for nothing.  Where I still have 
a choice, I must fight to maintain it, lest that thin edge of the 
wedge be pushed in further and further, until it becomes a 
thick edge, and then a wall.  ‘Rocephin’ for me is that issue, 
and I will not budge.  It is time we as a collective organisation 
of medical professionals stand up and say to those who would 
manipulate us ‘This far and no further’.
Martin Young
5 Hedge Street
Knysna
6571
1.  Lambert PA, Conway BR. Pharmaceutical quality of ceftriaxone generic products compared 
with Rocephin. J Chemother 2003; 15: 357-368.
Problematic childhood atopic eczema 
consensus document? 
To the Editor: The childhood atopic eczema consensus 
document published as part 2 of the June issue of the SAMJ1 is 
problematic and necessitates the following comments.
   A discussion of the controversy over the definition of atopic 
eczema is necessary, particularly in view of the recommen-
dations that pertain to allergy testing. Without this the rest of 
the article is open to misinterpretation. When dermatologists 
speak of atopic eczema they mean a clinical diagnosis. As 
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